Cover Image
Read Now

Pharmacoeconomic review report: Insulin degludec (Tresiba) (Novo Nordisk Canada Inc.)

Insulin degludec (Tresiba) is indicated for the treatment of adults with diabetes mellitus to improve glycemic control. The recommended daily starting dose of insulin degludec (IDeg) in type 2 diabetes mellitus (T2DM) patients who are insulin-naive is 10 units followed by individual dosage adjustmen...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2017, December 2017
Edition:Version: 1.0
Series:CADTH common drug review
Subjects:
Canada
Diabetes Mellitus / Drug Therapy
Insulin, Long-acting / Administration & Dosage
Cost-benefit Analysis
Hypoglycemic Agents / Therapeutic Use
Treatment Outcome
Insulin, Long-acting / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Insulin degludec (Tresiba) is indicated for the treatment of adults with diabetes mellitus to improve glycemic control. The recommended daily starting dose of insulin degludec (IDeg) in type 2 diabetes mellitus (T2DM) patients who are insulin-naive is 10 units followed by individual dosage adjustments. In type 1 diabetes mellitus (T1DM) patients, IDeg is to be used once daily with mealtime insulin and requires subsequent individual dosage adjustments. IDeg is supplied in a 3 mL FlexTouch pen for subcutaneous administration at a submitted price of $125.28 per 1,500-unit pack
Physical Description:1 PDF file (40 pages) illustrations

Similar Items